Adjuvant without active component

BIOLOGICAL4 trials

Sponsors

Affiris AG

Conditions

HypercholesterolemiaMultiple System AtrophyNeurodegenerative DiseasesParkinson DiseaseParkinson's Disease

Phase 1

Study Assessing Tolerability and Safety of AFFITOPE® PD03A in Patients With Early Parkinson's Disease

CompletedNCT02267434

Affiris AGNeurodegenerative Diseases, Parkinson Disease

Start: 2014-12-31End: 2016-08-31Updated: 2016-10-31

Study Assessing Safety and Therapeutic Activity of AFFITOPE® PD01A and PD03A in Patients With Early MSA

CompletedNCT02270489

Affiris AGMultiple System Atrophy, Neurodegenerative Diseases

Start: 2014-12-11End: 2017-04-18Updated: 2017-06-05

Study Assessing Safety, Immunogenicity and LDLc -Lowering Activity of 2 PCSK9 Targeting AFFITOPE Vaccines in Healthy Subjects

CompletedNCT02508896

Affiris AGHypercholesterolemia

Start: 2015-07-31End: 2017-08-31Updated: 2017-10-20

Study Assessing Tolerability and Safety and Exploring the Immunogenicity and Therapeutic Activity of AFFITOPE® PD01A in PD-GBA Patients

WithdrawnNCT02758730

Affiris AGParkinson's Disease

Updated: 2016-08-05

Related Papers

A phase I study assessing the safety, tolerability, immunogenicity, and low-density lipoprotein cholesterol-lowering activity of immunotherapeutics targeting PCSK9.

2021-05-1045 citations

A Phase 1 Randomized Trial of Specific Active <scp>α‐Synuclein</scp> Immunotherapies <scp>PD01A</scp> and <scp>PD03A</scp> in Multiple System Atrophy

Movement Disorders2020-09-0378 citations

Antibody-based immunotherapies for Parkinsonian syndromes

Neural Regeneration Research2019-01-014 citations